Detection of Angiotensin II type I‐receptor antibodies in transplant glomerulopathy

Abstract

AT R-Ab showed no independent prognostic role in TG in this pilot analysis.

Absence of IL-6 Receptor Blockade Effect on the Outcomes of Transplant Glomerulopathy in the Absence of Anti-HLA Donor-specific Antibodies

“…Alternatively, several studies have suggested the presence of DSA other than anti-HLA antibodies, 6 with many different antigens as their targets. 7 …”

“…Alternatively, several studies have suggested the presence of DSA other than anti-HLA antibodies, 6 with many different antigens as their targets. 7 Treatment of cAMR is an unmet need, considering that late allograft dysfunction is predominantly related to this condition, and no specific treatment has been approved to date. 1,8 The anti-interleukin (IL)-6 receptor antibody tocilizumab (TCZ) has been used in cAMR with promising results in reducing alloantibodies, ameliorating rejection lesions, and slowing renal function deterioration, 9 as also documented by our group.…”